AKT1 and hypophosphatemia: The most frequently reported grade ≥ 3 TEAEs included anemia, neutropenia, fatigue, and hypophosphatemia, which is consistent with the known safety profiles, and as expected for inhibition of the PI3K/AKT/mTOR pathway [23,34,37,38].